Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23

1.

Pharmacodynamics of plazomicin and a comparator aminoglycoside, amikacin, studied in an in vitro pharmacokinetic model of infection.

Noel AR, Attwood M, Bowker KE, Kim A, Krause KM, MacGowan AP.

Int J Antimicrob Agents. 2019 Nov;54(5):626-632. doi: 10.1016/j.ijantimicag.2019.07.001. Epub 2019 Jul 9.

PMID:
31299297
2.

Antibacterial effect of imipenem/relebactam on aerobic Gram-negative bacilli: in vitro simulations of 7 or 14 day human exposures.

Noel AR, Bowker KE, Attwood M, MacGowan AP.

J Antimicrob Chemother. 2019 Jul 1;74(7):1945-1951. doi: 10.1093/jac/dkz114.

PMID:
31220257
3.

Antibacterial effect of ceftolozane/tazobactam in combination with amikacin against aerobic Gram-negative bacilli studied in an in vitro pharmacokinetic model of infection.

Noel AR, Bowker KE, Attwood M, MacGowan AP.

J Antimicrob Chemother. 2018 Sep 1;73(9):2411-2417. doi: 10.1093/jac/dky225.

PMID:
30020472
4.

Pharmacodynamics of inhaled amikacin (BAY 41-6551) studied in an in vitro pharmacokinetic model of infection.

Bowker KE, Noel AR, Tomaselli S, Attwood M, MacGowan AP.

J Antimicrob Chemother. 2018 May 1;73(5):1305-1313. doi: 10.1093/jac/dky002.

PMID:
29562340
5.

Pharmacodynamics of minocycline against Acinetobacter baumannii studied in a pharmacokinetic model of infection.

Alfouzan WA, Noel AR, Bowker KE, Attwood MLG, Tomaselli SG, MacGowan AP.

Int J Antimicrob Agents. 2017 Dec;50(6):715-717. doi: 10.1016/j.ijantimicag.2017.06.026. Epub 2017 Jul 10.

PMID:
28705678
6.

Differences in the pharmacodynamics of ceftaroline against different species of Enterobacteriaceae studied in an in vitro pharmacokinetic model of infection.

Bowker KE, Noel AR, Tomaselli S, MacGowan AP.

J Antimicrob Chemother. 2016 May;71(5):1270-8. doi: 10.1093/jac/dkv480. Epub 2016 Feb 3.

PMID:
26846209
7.

Pharmacodynamics of Ceftolozane plus Tazobactam Studied in an In Vitro Pharmacokinetic Model of Infection.

MacGowan AP, Noel AR, Tomaselli SG, Nicholls D, Bowker KE.

Antimicrob Agents Chemother. 2015 Nov 9;60(1):515-21. doi: 10.1128/AAC.00727-15. Print 2016 Jan.

8.

Pharmacodynamics of ceftaroline against Staphylococcus aureus studied in an in vitro pharmacokinetic model of infection.

MacGowan AP, Noel AR, Tomaselli S, Bowker KE.

Antimicrob Agents Chemother. 2013 Jun;57(6):2451-6. doi: 10.1128/AAC.01386-12. Epub 2013 Mar 4.

9.

Comparative antibacterial effects of moxifloxacin and levofloxacin on Streptococcus pneumoniae strains with defined mechanisms of resistance: impact of bacterial inoculum.

Bowker KE, Garvey MI, Noel AR, Tomaselli SG, Macgowan AP.

J Antimicrob Chemother. 2013 May;68(5):1130-8. doi: 10.1093/jac/dks537. Epub 2013 Jan 29.

PMID:
23361641
10.

Pharmacodynamics of the antibacterial effect of and emergence of resistance to doripenem in Pseudomonas aeruginosa and Acinetobacter baumannii in an in vitro pharmacokinetic model.

Bowker KE, Noel AR, Tomaselli SG, Elliott H, Macgowan AP.

Antimicrob Agents Chemother. 2012 Oct;56(10):5009-15. doi: 10.1128/AAC.06111-11. Epub 2012 Jun 19.

11.

Evaluation of linezolid for the treatment of Clostridium difficile infection caused by epidemic strains using an in vitro human gut model.

Baines SD, Noel AR, Huscroft GS, Todhunter SL, O'Connor R, Hobbs JK, Freeman J, Lovering AM, Wilcox MH.

J Antimicrob Chemother. 2011 Jul;66(7):1537-46. doi: 10.1093/jac/dkr155. Epub 2011 Apr 18.

PMID:
21504940
12.

Pharmacodynamics of telavancin studied in an in vitro pharmacokinetic model of infection.

MacGowan AP, Noel AR, Tomaselli S, Elliott HC, Bowker KE.

Antimicrob Agents Chemother. 2011 Feb;55(2):867-73. doi: 10.1128/AAC.00933-10. Epub 2010 Nov 15.

13.

Bacterial strain-to-strain variation in pharmacodynamic index magnitude, a hitherto unconsidered factor in establishing antibiotic clinical breakpoints.

MacGowan AP, Reynolds R, Noel AR, Bowker KE.

Antimicrob Agents Chemother. 2009 Dec;53(12):5181-4. doi: 10.1128/AAC.00118-09. Epub 2009 Oct 5.

14.

Comparative antibacterial effects of daptomycin, vancomycin and teicoplanin studied in an in vitro pharmacokinetic model of infection.

Bowker KE, Noel AR, MacGowan AP.

J Antimicrob Chemother. 2009 Nov;64(5):1044-51. doi: 10.1093/jac/dkp289. Epub 2009 Sep 16.

PMID:
19759041
15.

Pharmacodynamics of minocycline against Staphylococcus aureus in an in vitro pharmacokinetic model.

Bowker KE, Noel AR, Macgowan AP.

Antimicrob Agents Chemother. 2008 Dec;52(12):4370-3. doi: 10.1128/AAC.00922-07. Epub 2008 Jun 2.

16.
17.

Pharmacodynamics of dalbavancin studied in an in vitro pharmacokinetic system.

Bowker KE, Noel AR, MacGowan AP.

J Antimicrob Chemother. 2006 Oct;58(4):802-5. Epub 2006 Aug 5.

PMID:
16891629
18.

Pharmacodynamics of moxifloxacin against anaerobes studied in an in vitro pharmacokinetic model.

Noel AR, Bowker KE, Macgowan AP.

Antimicrob Agents Chemother. 2005 Oct;49(10):4234-9.

19.
21.

In vitro activities of nine peptide deformylase inhibitors and five comparator agents against respiratory and skin pathogens.

Bowker KE, Noel AR, MacGowan AP.

Int J Antimicrob Agents. 2003 Dec;22(6):557-61.

PMID:
14659651
22.

Activity of AZD2563, a novel oxazolidinone, against Staphylococcus aureus strains with reduced susceptibility to vancomycin or linezolid.

Howe RA, Wootton M, Noel AR, Bowker KE, Walsh TR, MacGowan AP.

Antimicrob Agents Chemother. 2003 Nov;47(11):3651-2.

23.

Rapid continuous flow method for tissue processing.

Noel AR.

Lab Pract. 1972 Nov;21(11):815-6. No abstract available.

PMID:
5087179

Supplemental Content

Support Center